Small molecule targeting CELF1 RNA-binding activity to control HSC activation and liver fibrosis

Yang Tan,Xueqing Sun,Yizhu Xu,Bingjie Tang,Shuaiqi Xu,Dong Lu,Yan Ye,Xiaomin Luo,Xu Diao,Fulong Li,Tianyi Wang,Jiayu Chen,Qiang Xu,Xingxin Wu

DOI: https://doi.org/10.1093/nar/gkac139

IF: 14.9

2022-03-02

Nucleic Acids Research

Abstract:Abstract CUGBP Elav-like family member 1 (CELF1), an RNA-binding protein (RBP), plays important roles in the pathogenesis of diseases such as myotonic dystrophy, liver fibrosis and cancers. However, targeting CELF1 is still a challenge, as RBPs are considered largely undruggable. Here, we discovered that compound 27 disrupted CELF1-RNA binding via structure-based virtual screening and biochemical assays. Compound 27 binds directly to CELF1 and competes with RNA for binding to CELF1. Compound 27 promotes IFN-γ secretion and suppresses TGF-β1-induced hepatic stellate cell (HSC) activation by inhibiting CELF1-mediated IFN-γ mRNA decay. In vivo, compound 27 attenuates CCl4-induced murine liver fibrosis. Furthermore, the structure-activity relationship analysis was performed and compound 841, a derivative of compound 27, was identified as a selective CELF1 inhibitor. In conclusion, targeting CELF1 RNA-binding activity with small molecules was achieved, which provides a novel strategy for treating liver fibrosis and other CELF1-mediated diseases.

biochemistry & molecular biology